MHC-HM418T-100μg / 询价
MHC-HM418T-500μg / 询价
MHC-HM418T-500μgx2 / 询价
- 客服电话
- 技术支持
Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein
Recombinant Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*03:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide [Accession | NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAVGVGK].
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per ug by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody, hFc Tag with the EC50 of 0.18μg/ml determined by ELISA (QC Test).
Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody captured on CM5 Chip via Protein A can bind Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag with an affinity constant of 42.3 nM as determined in SPR assay (Biacore T200).
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
